Want to see ATEC full AI Analyst Report?
Top Page
Alphatec Holdings
(NASDAQ:ATEC)
Select Model
Select Model
Rating:62Neutral
Price Target:
$11.00
▲(33.17% Upside)
Action:Reiterated
Date:08/05/26
ATEC’s score is driven primarily by improving operating execution and upbeat guidance (raised EBITDA outlook, margin progression, and improving liquidity), supported by favorable near-term technical momentum. Offsetting this are meaningful balance-sheet leverage/negative equity and continued net losses, with valuation constrained by a negative P/E and no dividend yield data.
Positive Factors
Improved cash generation
ATEC's shift from multi-year negative OCF to positive trailing‑12‑month operating cash flow (~$56.5M) and slightly positive free cash flow reflects durable operating improvements and working capital discipline. Sustained positive cash generation increases flexibility to fund growth, reduce leverage, and invest in product rollout over the next several quarters.
Negative Factors
High leverage and negative equity
Elevated total debt (~$600M+) combined with slightly negative trailing equity weakens the capital structure and reduces financial flexibility. High leverage increases interest and covenant sensitivity, limits capacity for opportunistic M&A or R&D spending, and makes the firm more vulnerable to demand or margin shocks over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved cash generation
ATEC's shift from multi-year negative OCF to positive trailing‑12‑month operating cash flow (~$56.5M) and slightly positive free cash flow reflects durable operating improvements and working capital discipline. Sustained positive cash generation increases flexibility to fund growth, reduce leverage, and invest in product rollout over the next several quarters.
Read all positive factors
Alphatec Holdings (ATEC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.51B
Dividend YieldN/A
Average Volume (3M)2.81M
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth19.47%
EPS Growth36.87%
CountryUS
Employees913
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.72
Shares Outstanding154,451,080
10 Day Avg. Volume1,932,133
30 Day Avg. Volume2,805,832
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)87.63
Price to Sales (P/S)4.13
P/FCF Ratio1.14K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.00Price Target Upside81.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.32
Revenue Forecast (FY)$882.06M
Alphatec Holdings Business Overview & Revenue Model
Company Description
Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX ...
How the Company Makes Money
ATEC primarily makes money by selling spine-surgery products and related procedural solutions to hospitals and surgical centers, largely through direct sales and distributor channels. Key revenue streams include: (1) spinal fixation systems (e.g.,...
Alphatec Holdings Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call highlights a strong quarter: double-digit revenue growth, robust surgeon adoption and case volume gains, meaningful gross margin expansion, sharply higher adjusted EBITDA and improved liquidity, plus raised profitability guidance. Headwinds are largely mix-related (international and cervical), a continued shortfall in biologics attachment rates that pressured revenue per case, early-stage EOS Insight penetration and front-loaded investments in inventory and sets that compress near-term free cash flow. Management presented concrete paths to mitigate these issues (product launches, sales discipline, EOS/Insight adoption, and balance-sheet improvements) and expressed confidence in the back half and into 2027.Positive Updates
Strong Revenue Growth
Total revenue of $214M in Q2, up 15% year-over-year; surgical revenue $196M, up 17% YoY (+$28M vs prior year).
Negative Updates
Revenue per Case Pressure
Overall revenue per case declined ~2.7% YoY in Q2 (driven by case mix and international growth); company now expects average revenue per case to decline low single digits for the full year.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Total revenue of $214M in Q2, up 15% year-over-year; surgical revenue $196M, up 17% YoY (+$28M vs prior year).
Read all positive updates
Company Guidance
ATEC maintained full‑year revenue guidance of approximately $882 million (≈15% growth), including surgical revenue of about $805 million (≈17% growth) and EOS revenue of roughly $77 million, and raised adjusted EBITDA guidance to ~ $140 million (≈16% margin, up from a prior outlook of $134M). Management expects high‑teens surgical case volume growth in H2 (implying H2 surgical revenue growth of ≈18% vs. 17% in H1), average revenue per case to decline in the low single digits for the full year, at least $20 million of free cash flow for 2026 (Q3 FCF guided at $4–6M), and continued margin progression. The guidance is supported by Q2 results of $214M revenue (+15% YoY) with surgical $196M (+17%), EOS $17M, adjusted EBITDA $36M (17% margin), gross margin 72.5% (up 260 bps), ~$119M cash and $85M available borrowing capacity (~$204M total liquidity), and a new credit package extending maturities to 2031 and reducing annual interest expense by >$6M.Alphatec Holdings Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
22
Negative
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 815.05M | 764.15M | 611.56M | 482.26M | 350.87M | 243.21M |
| Gross Profit | 539.13M | 531.89M | 424.26M | 310.20M | 233.06M | 157.76M |
| EBITDA | 13.46M | -39.70M | -53.87M | -110.59M | -102.58M | -106.88M |
| Net Income | -109.99M | -143.36M | -162.12M | -186.64M | -151.29M | -143.03M |
Balance Sheet | ||||||
| Total Assets | 791.03M | 791.21M | 775.71M | 805.21M | 520.97M | 572.05M |
| Cash, Cash Equivalents and Short-Term Investments | 118.66M | 160.81M | 138.84M | 220.97M | 84.70M | 187.25M |
| Total Debt | 604.02M | 619.95M | 609.94M | 541.68M | 395.86M | 355.43M |
| Total Liabilities | 803.10M | 755.18M | 766.28M | 703.49M | 555.63M | 492.63M |
| Stockholders Equity | -12.07M | 36.03M | 9.43M | 101.72M | -34.67M | 79.42M |
Cash Flow | ||||||
| Free Cash Flow | 4.16M | 2.78M | -137.79M | -165.46M | -133.41M | -141.86M |
| Operating Cash Flow | 56.52M | 45.23M | -44.65M | -78.48M | -75.13M | -73.32M |
| Investing Cash Flow | -72.23M | -53.41M | -93.14M | -141.97M | -58.28M | -157.76M |
| Financing Cash Flow | -22.41M | 30.02M | 56.21M | 356.92M | 31.23M | 311.97M |
Alphatec Holdings Technical Analysis
Positive
8.26
Price Trends
8.95
Positive
9.27
Positive
13.29
Negative
Market Momentum
0.22
Negative
57.50
Neutral
55.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATEC, the sentiment is Positive. The current price of 8.26 is below the 20-day moving average (MA) of 9.23, below the 50-day MA of 8.95, and below the 200-day MA of 13.29, indicating a neutral trend. The MACD of 0.22 indicates Negative momentum. The RSI at 57.50 is Neutral, neither overbought nor oversold. The STOCH value of 55.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATEC.
Alphatec Holdings Risk Analysis
Alphatec Holdings disclosed 39 risk factors in its most recent earnings report. Alphatec Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alphatec Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $11.53B | 21.64 | 11.59% | ― | 19.74% | 51.10% | |
74 Outperform | $19.20B | 24.37 | 6.36% | 1.05% | 8.62% | 0.09% | |
72 Outperform | $130.11B | 34.86 | 16.36% | 1.05% | 8.48% | 27.36% | |
68 Neutral | $116.83B | 24.34 | 9.85% | 3.43% | 8.43% | 3.17% | |
62 Neutral | $1.51B | -13.60 | -818.99% | ― | 19.47% | 36.87% | |
55 Neutral | $421.18M | -6.73 | -14.05% | ― | 2.99% | 51.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ATEC
Alphatec Holdings
9.79
-6.07
-38.27%
MDT
Medtronic
91.27
1.38
1.54%
OFIX
Orthofix Medical
10.34
-4.17
-28.74%
SYK
Stryker
339.21
-38.55
-10.21%
ZBH
Zimmer Biomet Holdings
100.65
-0.84
-0.83%
GMED
Globus Medical
85.90
25.65
42.57%
Alphatec Holdings Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Alphatec Shareholders Approve 2026 Equity and ESPP Plans
Positive
Jun 11, 2026
On June 10, 2026, Alphatec Holdings, Inc. shareholders approved the company’s 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the 2026 annual meeting, making both plans effective upon approval and reinforcing equity-based...
Business Operations and StrategyPrivate Placements and Financing
Alphatec Establishes New Syndicated Credit Facility for Growth
Positive
May 5, 2026
On May 1, 2026, Alphatec Holdings entered into a new senior secured credit agreement comprising a $175 million Term Loan A and a $125 million revolving credit facility led by JPMorgan Chase and TD Securities, its first syndicated bank facility. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.